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derma Stem Cell vs Immune Suppression Trial), comparing
HSCT to IV pulse CY is now enrolling patients.
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LONG TERM REMISSION IN SEVERE AND REFRACTORY LUPUS (SLE)
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Arnold, R.1, Massenkeil, G.1, Tamm, I.1, Alexander, T.2, Thiel, A.3,
Radbruch, A.3, Hiepe, F.2 1. Department of Internal Medicine, Hema-
tology/Oncology, Charite´ University Medicine Berlin, Berlin, Germany;
2. Department of Internal Medicine, Rheumatology, Charite´ University
Medicine Berlin, Berlin, Germany; 3. German Rheumatism Research
Centre, Berlin, Germany.
The concept of autologous stem cell transplantation (ASCT) is a
resetting of the immune system. High dose chemotherapy and
immune ablation destroys the immune system (autoreactivity) of
the patient followed by a T cell depleted stem cell transplant with
development of a tolerant immune system. Seven patients (age
19–48 years) with life threatening SLE characterized by severe
organ involvement with persistent active disease despite treatment
with standard immunosuppressive drugs were treated in the Berlin
phase I/II trial since 1998 with a median follow up of 55 (8–90)
months. Treatment includes mobilization of hematopoietic stem
cells with cyclophosphamide (CY) 2 g/m2 and G-CSF (10 ug/kg/
day), leukapheresis and enrichment of CD34 cells, conditioning
with CY 200 mg/kg and rabbit antithymocyte globuline (ATG) 90
mg/kg followed by ASCT. Clinical and serological remission could
be achieved in 7/7 patients. One of 7 patients died due to cerebral
aspergillosis on d  90, 1 patient had a ﬂare at 17 months and died
due to uncontrolled SLE 36 months post ASCT. At the time of
ﬂare change of autoantibody proﬁle occurred and naive Th-cells
and naive B-cells declined compared to the remission patients. Five
patients are alive in clinical remission. These patients are autoan-
tibody negative and no autoreactive Th-cells directed to nucleo-
some could be detected after ASCT. One of these patients gave
birth to a healthy boy 35 months post ASCT. Open questions in
ASCT for treatment of SLE are: Is TRM associated with stage of
disease at ASCT/intensive pretreatment? Why do some patients
relapse? Methods of prevention of relapse after ASCT? In Ger-
many, a multicenter clinical trial protocol is initiated to answer
these questions.
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VIRAL INFECTIONS DURING CD34 CELLS PURIFIED AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR THE TREAT-
MENT OF REFRACTORY AUTOIMMUNE DISEASES
Nagafuji, K.1, Tsukamoto, H.1, Numata, A.1, Miyamoto, T.2,
Harada, M.1 1. First Department of Internal Medicine, Kyushu Uni-
versity Hospital, Fukuoka, Japan; Center for Cellular and Molecular
Medicine, Kyushu University Hospital, Fukuoka, Japan.
Aims: We retrospectively analyzed viral infections during
CD34 cells autologous peripheral blood stem cell transplantation
(PBSCT) for the treatment of refractory autoimmune diseases
(AD). Materials and Methods: 9 cases of systemic sclerosis (SSc)
with interstitial pneumonia(IP),1 case of amyopathic dermatomy-
ositis (ADM) with IP, 1 case of Wegener granulomatosis (WG)
with exophthalmous. Except one SSc patient No. 9, all patients had
been treated with steroid, and were administered with steroid
during peri-transplant period. PBSC were mobilized with cyclo-
phosphamide (CY) 4 g/m2G-CSF, and CD34 cells were puri-
ﬁed with CliniMACS. Pre-transplant conditioning consisted of CY
200 mg/kg. Acyclovir (ACV) 250 mg/day was administered from
day1 to day 35. Result: Before PBSC mobilizations, patient No. 2
with ADM was positive for cytomegalovirus (CMV) antigenemia
and treated with gancyclovir (GCV). After PBSC mobilizations, 3
patients became positive for CMV antigenemia (3/11 27%) treated
with GCV, and 1 patient developed genital herpes simplex virus
infection treated with ACV. After transplantations, 5 out of 11
patients (45%) became positive for CMV antigenemia treated with
GCV. Median day becoming positive for CMV antigenemia was
22.5 days post-transplant ranging 10 to 38 days. Two patients,
No.1 and No. 8 (18%), developed adenoviral hemorrhagic cystitis
(adeno HC) on day 64 and day 33, respectively, treated with
cidofovir (CDV).Discussion: Before transplantations, most of AD
patients had received immunosuppressive therapy. CD34 cells
PBSCT is an immunosuppressive therapy. Thus, during peri-
transplant period, AD patients developed various viral infections.
Infection surveillance and diagnostic work-up, same as with those
used in allogeneic recipients seem to be necessary (Table1).
Patient
No.
Age/
Sex Diseases
Pre-
mobilization
Steroid Tx
Pre-
mobilization
Viral
Infections
Post-
mobilization
Viral
Infections
Post-
transplant
Viral
Infection
1 54/F SSc/IP yes day 38
CMV,
day 64
adeno
HC
2 54/F ADM/IP yes CMV CMV day 21
CMV
3 55/M SSC/IP yes CMV
4 58/M SSc/Ip yes day 10
CMV
5 54/F SSc/IP yes day 24
CMV
6 53/F SSC/IP yes
7 21/M WG yes
8 49/F SSc/IP yes CMV day 31
adeno
HC, day
33 CMV
9 33/F SSc/IP no
10 63/F SSc/IP yes genital HSV
11 61/F SSc/IP yes CMV day 21
CMV
AUTOLOGOUS
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TARGETED TOTAL MARROW IRRADIATION USING 3D IMAGE GUIDED
TOMOGRAPHIC INTENSITY MODULATED RADIATION THERAPY: AN
ALTERNATIVE TO STANDARD TBI
Wong, J.Y.C.1, Liu, A.1, Schultheiss, T.1, Popplewell, L.1, Stein, A.1,
Rosenthal, J., Forman, S.1, Somlo, G.1 City of Hope Cancer Center,
Duarte, CA.
Purpose: TBI is an important part of many hematopoietic stem
cell transplant (HSCT) conditioning regimens. Dose escalation of
TBI has been difﬁcult due to associated organ toxicities. A method
to deliver a more targeted dose of TBI to sites of greatest tumor
burden is needed to reduce dose to normal organs, reduce toxici-
ties, and permit dose escalation. The purpose of this study was to
evaluate the delivery of targeted myeloablative doses of radiation to
bone and marrow using a recently developed image guided tomo-
graphic intensity modulated radiation therapy delivery system (to-
motherapy). Methods: CT data sets from 3 patients (2 AML and
1 multiple myeloma) were used for dosimetry planning studies to
evaluate two strategies: total marrow irradiation (TMI), where the
target region was deﬁned as the skeletal bone, and total marrow
and lymphoid irradiation (TMLI), where the target regions were
deﬁned as bone, major lymph node chains, liver, spleen, and sanc-
tuary sites, such as brain. Organ doses and dose distributions were
compared to conventional TBI. Results: A 1.7 to 7.5-fold reduc-
tion in median organ dose was observed with TMI and TMLI
compared to conventional TBI. Dose-volume histogram analysis
predicted for the potential to escalate dose to bone and marrow up
to 20 Gy with TMI, while maintaining doses to normal organs at
lower levels compared to conventional TBI to 12 Gy (Table).
Results were similar for the adult and pediatric patients indicating
that this method will be applicable to most patients regardless of
frame size. TMI to 10 Gy was delivered as part of an autologous
tandem transplant regimen to the patient with multiple myeloma.
Clinical results conﬁrmed treatment planning predictions. After
TMI, the patient experienced the expected blood count nadir,
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